TC BioPharm Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Loss before tax

Loss before tax

12 Months Ended

Dec. 31, 2022

Loss before tax

5. Loss before tax

Loss before tax is stated after charging the following:

Schedule of operating loss

		Year ended December 31,				Year ended December 31,				Year ended December,31
		2022				2021				2020
		£				£				£
Included in research and development costs:
Depreciation of property, plant and equipment			683,475				730,730				784,099
Amortization of intangible assets			55,046				63,451				51,889
Amortization of right of use assets			174,954				174,953				172,987

Included in administrative expenses:
Loss/(gain) on foreign exchange			-				(17,781	)			1,891
Depreciation of property, plant and equipment			31,075				34,301				42,651
Amortization of right of use assets			21,623				21,623				23,589